Ftse Mib
36.471,75
0,12%
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
101.173,31
0,50%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Genmab AS (GMAB) Genmab AS (GMAB) Notizie

Genmab AS

GMAB
19,67
-0,14 (-0,71%)
01 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
29/1/202518:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/12/202418:00BWTwo Data Analyses from Clinical Trials Show Epcoritamab..
08/12/202417:00BWInvestigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy..
08/12/202401:00BWInvestigational Epcoritamab (DuoBody® CD3xCD20) Combination..
04/12/202417:26EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/12/202422:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/12/202417:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/11/202418:54EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202420:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/11/202418:00BWGenmab to Showcase Strength and Breadth of Comprehensive..
15/9/202414:45BWInvestigational Rinatabart Sesutecan (Rina-S) Shows..
11/9/202421:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/9/202422:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/8/202416:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/8/202420:00BWTEPKINLY® (epcoritamab) Receives Second European Commission..
16/8/202415:00BWGenmab Announces Changes to its Executive Committee
14/8/202416:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/8/202420:57EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/8/202412:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/7/202416:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/6/202408:00BWEpcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for..
27/6/202401:08BWEPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for..
12/6/202421:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/6/202421:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/6/202418:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/6/202422:23EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/6/202415:00BWInvestigational Tisotumab Vedotin Phase 2 Data Demonstrates..
02/6/202423:30BWPreliminary Analysis of Data Evaluating Investigational..
01/6/202416:00BWInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in..
28/5/202417:29EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/5/202423:00BWGenmab to Showcase Data in Various Patient Populations to be..
21/5/202417:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/5/202417:18EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/5/202417:10BWGenmab Completes Acquisition of ProfoundBio
14/5/202416:05BWGenmab to Present New and Updated Results From Multiple..
13/5/202417:29EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/4/202400:40BWTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval..
03/4/202407:35BWGenmab to Broaden and Strengthen Oncology Portfolio with..
11/3/202418:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/3/202419:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/3/202419:26EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/3/202423:04EDGAR2Form 144 - Report of proposed sale of securities
29/2/202417:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202417:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/2/202422:55EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/2/202413:45BWU.S. FDA Accepts for Priority Review the Supplemental..
26/2/202418:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/2/202416:40EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/2/202422:28EDGAR2Form S-8 - Securities to be offered to employees in employee..
20/2/202417:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
Apertura: 19,78 Min: 19,61 Max: 19,97
Chiusura: 19,81

La tua Cronologia

NASDAQ
GMAB
Genmab AS
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci